Patent · US Active

Dosage of oligonucleotides suitable for the treatment of tumors

US8822425B2 · kind B2 · utility

2Cited by

2References

8Claims

0Family size

Assignee

Antisense Pharma GmbH · DE

Inventors

Karl-Hermann Schlingensiepen · Bovenden, DE
Hubert Heinrichs · Regensburg, DE
Susanne Schmaus · Bad Abbach, DE

Key dates

Filing date	May 12, 2009
Grant date	Sep 2, 2014
Priority date	—
Expiry date	Jun 24, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/32
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

A method for preventing and/or treating a tumor, the method comprising: intravenously administering an antisense oligonucleotide in an amount of between about 400 to about 800 mg/m2/treatment cycle, the antisense oligonucleotide comprises 8 to 30 nucleotide building blocks, which hybridizes with mRNA of TGF-beta-2, -1 and/or -3 for the preparation of a pharmaceutical composition.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.